Editorial Commentary
Link to the document: https://academic.oup.com/europace/advance-article/doi/10.1093/europace/euag080/8651392?guestAccessKey=
Introduction:
This document consolidates and synthesizes the preclinical and clinical evidence on pulsed-field ablation (PFA), establishing its biological basis and technology, and comparing it to thermal energy therapies. It provides a taxonomy of platforms and practical recommendations for implementation, workflow, and standardized training. It reviews efficacy and safety data (randomized trials and large registries), highlighting primarily the absence of esophageal damage and the more expeditious nature of the procedures. It identifies emerging safety signals (vasospasm, hemolysis, cerebrovascular events) and the need for harmonized surveillance. It establishes research priorities: parameter transparency, long-term durability, use of mapping systems, and cost-effectiveness studies.
Critical Analysis by Thematic Blocks
1) Biophysics of Injury
– The document offers a clear technical explanation of irreversible electroporation: the effect of the electric field on the membrane, tissue thresholds, injury zones, and differences compared to RF/cryo. It incorporates preclinical evidence that explains cardiomyocyte selectivity.
– Conceptual limitations: the guideline acknowledges the lack of standardization in waveform parameters (amplitude, duration, number of pulses), and that many details remain proprietary and have not been published. This hinders extrapolation between platforms and dose-response modeling. Furthermore, the mechanistic explanation does not fully resolve the occurrence of non-selective effects (vasospasm, hemolysis), the mechanism of which requires targeted translational studies.
2) Technology and Platform Heterogeneity
– Contribution: operational classification of catheters (regional/large-tip/focal) and comparative detail of parameters (monopolar/bipolar mode, amplitude, duration, need for electroanatomical maps, and use of ICE). Practical recommendations on dosage and safety by catheter type are provided.
– Critical assessment: technological heterogeneity appears to be the most influential factor in the variability of clinical and safety outcomes. The document underscores the need for terminological harmonization and minimum standards, but does not define universal metrics for “PFA dose” or safety thresholds. For comparative research, a regulatory-scientific framework requiring technical disclosure (waveform, duty cycle) and standardized preclinical trials would be necessary.
3) Clinical Evidence: Efficacy and Comparative Studies
– Contribution: Summary of five randomized trials comparing PFA with RF or cryotherapy in PAF and one in PsAF (SPHERE Per-AF), with results showing non-inferiority in efficacy, shorter procedure time, and apparently favorable complication profiles. Extensive compilation of pivotal studies and registries (admIRE, PULSED-AF, MANIFEST, MANIFEST-17k, EU-PORIA).
– Critical Analysis: Although the RCTs show non-inferiority, heterogeneity in design, rhythmic monitoring (24-hour Holter vs. insertable Holter monitors), endpoint definitions, and follow-up limits conclusive meta-analyses. Furthermore, most data are available at 12 months; series with long-term follow-up (>3–5 years) are lacking to assess lesion durability and late events. Additionally, most evidence focuses on specific catheters (pentaspline, lattice)—insufficient to generalize to all platforms.
4) Safety Profile: Advantages and Emerging Signals:
– Described advantages: low incidence of atrioesophageal stenosis reported in large series (no cases in >500,000 procedures cited for certain catheters), low clinical pulmonary stenosis, and less persistent phrenic nerve injury.
– Emerging signals and areas of caution:
– Hemolysis and acute renal failure linked to blood-electrode interaction and number of applications. Design-dependent risk; requires preventive measures (hydration, monitoring).
– Coronary vasospasm, especially in linear interventions or near coronary arteries (mitral isthmus, ICT); and the possible mitigation with intracoronary/IV nitroglycerin described. Cerebrovascular events: variability between systems with stroke rates detected by neuro-MRI; possible multifactorial relationship (air, thrombus, catheter design). Heterogeneous data and the need for specific anti-embolic protocols.
– Interaction with intracardiac devices (CIED, LAAO): reports of software resets/errors and pulse aborts due to contact with metallic devices (Fig. 3, p. 100); pre/post questioning and avoiding direct contact are recommended.
– Conclusion: “Improved” safety regarding thermal risks does not mean the absence of adverse effects; they appear
5) Workflow and Procedural Endpoints
– Practical contributions: guidelines on sedation (preference for deep sedation in many centers), use of ICE and/or EAM, ACT control and management of air embolism, isolation verification strategies (entrance/exit block), and the relative role of adenosine or waiting times.
– Assessment: the document offers acceptable alternatives (fluoroscopy-only, ICE, EAM), but emphasizes that the assessment of “contact” and “dosage” differs from RF. Prospective evidence is lacking to indicate which combination of tools (ICE+EAM vs. fluoroscopy only) optimizes durability and minimizes complications per platform.
6) Training, Credentials, and Clinical Adoption
– Proposal: integration of PFA into the curricula of different scientific societies, a structured step-by-step approach with simulation, access to proctorates, preceptorships, and competency metrics. List of technical and non-technical skills.
– Evaluation: the guide correctly emphasizes the need for training. However, minimum case/supervision thresholds for accreditation and audit/registration systems that incorporate outcomes and complications per operator/center are required.
In summary:
– This document provides a robust and multidimensional synthesis on PFA, with practical contributions and prudent recommendations. It highlights the clinical promise (comparable efficacy and improved profile in thermal injuries) while also acknowledging significant uncertainties: technological heterogeneity, design-dependent adverse effects, and a lack of long-term data. The evidence supports the controlled adoption of PFA for PVI in trained centers, with the urgent need for technical standardization, surveillance programs, and long-term studies to determine durability and safety in indications beyond PVI. Finally, it makes clear that a single “class effect” for PFA cannot be assumed. PFA technologies are not identical. Each platform needs to be evaluated with comparative studies, systematic remapping, and post-marketing surveillance, and standardization of parameters must be promoted to allow for valid comparisons.
Author:
Armando Pérez-Silva, MD, PhD
- Cardiologist-Electrophysiologist
- Regional Hospital of Concepción, Chile
- Secretary-Elect, LARHS